You are here: Industry Insights > Eli Lilly

News List

Lilly's Tirzepatide Reduced A1C, Body Weight for Type 2 Diabetes americanpharmaceuticalreview
December 10, 2020
Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety ...
Baricitinib Receives EUA for Hospitalized Patients with COVID-19 americanpharmaceuticalreview
December 07, 2020
Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult ...
Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19 contractpharma
December 07, 2020
The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions.
US buys additional 650,000 doses of Lilly’s Covid-19 antibody for $812.5m pharmaceutical-technology
December 04, 2020
The US government has entered into a purchase agreement worth $812.5m to procure 650,000 additional doses of Eli Lilly and Company’s neutralising antibody bamlanivimab (LY-CoV555) 700mg.
Lilly, Samsung Partner to Mass Produce COVID-19 Antibody americanpharmaceuticalreview
November 25, 2020
Samsung Biologics' partnership with Eli Lilly and Company is expected to accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the goal of making antibody treatments more globally ...
Lilly to collaborate with Precision BioSciences on genome editing research pharmatimes
November 24, 2020
Eli Lilly has entered a research collaboration and exclusive license agreement with Precision BioSciences to use genome editing to develop therapies for genetic disorders.
FDA grants EUA for Lilly and Incyte’s baricitinib for Covid-19 treatment pharmaceutical-technology
November 23, 2020
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for Eli Lilly and Company and Incyte’s baricitinib in combination with remdesivir in hospitalised patients with Covid-19.
Samsung Biologics Partners with Eli Lilly contractpharma
November 23, 2020
Samsung Biologics has entered a strategic manufacturing partnership with Eli Lilly to accelerate the global supply for Lilly’s Covid-19 antibody therapies with the ultimate goal of making antibody treatments more globally accessible for patients.
NICE recommends Lilly’s migraine med Emgality pharmatimes
November 20, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Emgality as a preventative treatment for migraine in adults with episodic and chronic migraine.
Olumniant (barcitinab) from Eli Lilly gets EUA from US FDA for COVID-19 treatment expresspharma
November 20, 2020
The US Food and Drug Administration (USFDA) issued an emergency use authorisation (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults and pediatric ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page